Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neoplasm, Residual × Clonal Evolution × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1

Interventions

Cyclophosphamide 7 fludarabine 5 Cytarabine 5 blinatumomab 4 Methotrexate 4 Mercaptopurine 4 fludarabine phosphate 3 Vincristine 3 Rituximab 3 Granulocyte Colony-Stimulating Factor 3 Etoposide 3 Dexamethasone 3 Daunorubicin 3 Asparaginase 3 Whole-Body Irradiation 2 Vindesine 2 Thioguanine 2 Teniposide 2 Stem Cell Transplantation 2 Prednisolone 2 N,N-dicyclohexyl-isoborneol-10-sulfonamide 2 Interleukin-2 2 Drug Therapy 2 Doxorubicin 2 Cladribine 2 Blood Specimen Collection 2 Azacitidine 2 tisagenlecleucel 1 thymoglobulin 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03521596 2025-11-18

FIL_BIOWM

Fondazione Italiana Linfomi - ETS

Waldenstrom Macroglobulinemia, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡